R&D

PIPELINE

SoVarGen will continue to expand competitive pipelines through our
proprietary science and technology.

SoVarGen R&D Pipeline
Neurodevelopmental disorders Brain Tumor Neurodegenerative diseases
SoVarGen R&D Pipeline
Pipeline / Indication Discovery Pre-clinical Clinical
Target
identification		 Lead
optimization		 Proof of
concept		 IND-enabling
studies		 Phase 1 Phase 2
SVG101 Intractable focal epilepsy
IND-enabling
SVG102 Intractable focal epilepsy
IND-enabling
SVG103 Non-disclosure
Lead optimization
SVG104 Non-disclosure
Target identification
SVG301 Non-disclosure
Target identification
SVG302 Glioblastoma multiforme
Target identification
SVG501 Alzheimer’s disease
Target identification

SVG101 FCD 2

SVG102 FCD 2

SVG103 Non-disclosure

SVG104 Non-disclosure

SVG301 Non-disclosure

SVG302 Glioblastoma multiforme

SVG501 Alzheimer’s disease

Partnership

SoVarGen will expedite and strengthen drug development with our unique
science and technology and also through open collaboration with global partners.

  • Bioinformatics & Artificial Intelligence

    SoVarGen is awaiting its partners to collaborate on articulating root causes and mechanisms of CNS diseases and create a transformational long-term platform.
    Programs for Cooperation
    • Genomic data base target discovery
    • In vitro and in vivo Target validation
    • RNA drugs candidate screening & optimization

  • RNA
    Therapeutics

    SoVarGen is awaiting its partners to design and materialize a new gene treatment technology
    Programs for Cooperation
    • ASO, siRNA therapy
    • mRNA therapy
    • chemical modification of ASO, siRNA, mRNA
    • Gene editing

  • Delivery System Development

    SoVarGen is awaiting its partners to develop new drug delivery systems by which the in vivo stability and the permeability of the blood-brain barrier or BBB, will be further enhanced.
    Programs for Cooperation
    • Liposome
    • Exosome
    • Viral Vector

  • New Disease Models

    SoVarGen is awaiting its partners to build disease-specific animal models with the new gene -editing technology to validate the stability and effectiveness of candidate substances.
    Programs for Cooperation
    • Human brain organoid, iPSC
    • Genetic engineered animal model